1. Home
  2. |Professionals
  3. |Eline D'Joos

Eline D'Joos

Associate | She/Her/Hers
Associate | She/Her/Hers
ZWRqb29zQGNyb3dlbGwuY29t
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Eline D’Joos is a life sciences associate in Crowell & Moring’s Brussels office. Her practice focuses on regulatory issues and commercial transactions in the life science sector, as well as interplays with general intellectual property and data protection questions. 

Eline has advised multinational companies and start-ups as well as research institutes in the pharmaceutical, biotech, and medical devices sectors on a variety of complex matters, including clinical trials, product approvals, regulatory incentives, market access, biosimilars, orphan drugs, pediatrics, and Belgian supplementary protection certificates. Digital transformation in the health sector is also one of Eline’s main focus areas.

Eline also has experience in drafting and negotiating high value IP licenses, R&D collaborations, and commercial agreements. In addition, she has assisted with mergers and acquisitions of life sciences companies as well as patent infringement proceedings and preliminary injunctions.

Career & Education

    • Catholic University of Leuven, Bachelor of law, magna cum laude (best bachelor student award), 2017
    • Catholic University of Leuven, Research master of law, magna cum laude, 2019
    • Catholic University of Leuven, Master of education, cum laude, 2020
    • Catholic University of Leuven, Bachelor of law, magna cum laude (best bachelor student award), 2017
    • Catholic University of Leuven, Research master of law, magna cum laude, 2019
    • Catholic University of Leuven, Master of education, cum laude, 2020

    • Belgium
    • Belgium

    • Dutch
    • English
    • French
    • Dutch
    • English
    • French

Eline's Insights

Client Alert | 7 min read | 12.15.25

The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package

On December 11, 2025, the Council of the European Union and the European Parliament reached provisional agreement on the long-awaited “Pharma Package,” (see the announcement here). The Pharma Package is a comprehensive and major overhaul of the EU legislative framework for pharmaceuticals, which replaces the more than 20-year-old Directive 2001/83 and Regulation 726/2004 and incorporates (and updates) the separate regulations on orphan and pediatric medicines (Regulations 141/2000 and 1901/2006 respectively)....

View All Insights

Insights

Client Alert | 7 min read | 12.15.25

The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package

Press Coverage | 11.07.25

Critical Medicines Act : un texte décisif pour l'industrie pharma en Belgique ?

Press Coverage | 11.07.25

Critical Medicines Act: un texte décisif pour l'industrie pharma en Belgique?

Press Coverage | 10.23.25

Le « Critical Medicines Act », ce plan européen qui pourrait changer la donne pour la Belgique

View All Insights

Practices

Industries

Eline's Insights

Client Alert | 7 min read | 12.15.25

The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package

On December 11, 2025, the Council of the European Union and the European Parliament reached provisional agreement on the long-awaited “Pharma Package,” (see the announcement here). The Pharma Package is a comprehensive and major overhaul of the EU legislative framework for pharmaceuticals, which replaces the more than 20-year-old Directive 2001/83 and Regulation 726/2004 and incorporates (and updates) the separate regulations on orphan and pediatric medicines (Regulations 141/2000 and 1901/2006 respectively)....

View All Insights